Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 495 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ER-negative Breast Cancer Clear all
Completed Phase 1 Interventional

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316
View directory record Official record
Conditions
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions
AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 4, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

NCT00597597
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Erlotinib
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 4, 2026, 1:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

NCT02734290
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, Paclitaxel, Capecitabine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
Procedure · Other · Genetic + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 4, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

NCT01394211
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 4, 2026, 1:21 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT01818063
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Veliparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 4, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan In TNBC

NCT04230109
View directory record Official record
Conditions
Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
Sacituzumab Govitecan, Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 4, 2026, 1:21 AM EDT
Completed No phase listed Observational

Effects of Aromatase Inhibitor Therapy on Muscle Function

NCT03581552
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Not listed
Lead sponsor
Tarah J Ballinger, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 4, 2026, 1:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

NCT04576455
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

NCT01074970
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Rucaparib
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 1:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

NCT03941730
View directory record Official record
Conditions
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ZN-c5 in Subjects With Breast Cancer

NCT03560531
View directory record Official record
Conditions
Breast Cancer
Interventions
ZN-c5, Palbociclib
Drug
Lead sponsor
Zeno Alpha Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 4, 2026, 1:21 AM EDT
Active, not recruiting Phase 1 Interventional

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

NCT02208375
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

NCT06450873
View directory record Official record
Conditions
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions
Coriolus Versicolor Extract, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 4, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

Biology Guided Therapy for Breast Cancer for ER Positive

NCT04965688
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Biopsy-Guided Therapy Selection
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 4, 2026, 1:21 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059
View directory record Official record
Conditions
Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Interventions
ALTA2618
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
La Jolla, California • Denver, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 4, 2026, 1:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

NCT02457910
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 4, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

NCT04352777
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Abemaciclib, Fulvestrant, Aromatase Inhibitors
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 4, 2026, 1:21 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 4, 2026, 1:21 AM EDT